A practical reference on anti-doping testing: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-04 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
== Society and culture == Vaginal mesh kits were introduced to the U.S. market in 2004 through the U.S. Food and Drug Administration (FDA) pathway that did not require companies to demonstrate both safety and efficacy of the product if they were able to demonstrate that their product was similar to previous products already in the market. However, there was concern over reports of increased rates of postoperative complications over the next several years. That, in addition to the lack of available data that transvaginal mesh products were superior to other forms of surgical intervention and the expedited process which the vaginal mesh kits were introduced to the market, the FDA released a Safety Communication in 2011 that described serious complications associated with transvaginal mesh as "not rare". In 2019, the FDA ordered manufacturers to halt sales of transvaginal mesh intended for repair of pelvic organ prolapse. This does not include surgical mesh used during sacrocolpopexy, sacrohysteropexy, or transurethral sling procedures. Since 2008, a number of class action lawsuits have been filed and settled against several manufacturers of transvaginal mesh after people reported complications following surgery.
==== Rights restored ==== But on March 7, 2006, the Cherokee Nation Judicial Appeal Tribunal ruled that the Cherokee Freedmen were eligible for Cherokee citizenship. The Cherokee Freedman had historically been recorded as "citizens" of the Cherokee Nation since 1866, and their ancestors were recorded on the Dawes Commission Land Rolls (although generally in the category of Cherokee Freedmen, even if they qualified as "Cherokee by blood", as many did.) The ruling "did not limit membership to people possessing Cherokee blood," as some Freedmen and their descendants had never intermarried with Cherokees. Well-known genealogist, historian, and Freedmen advocate David Cornsilk notes that other historical citizenship bases are still excluded to this day (such as an ancestor tied to an older roll). On May 15, 2007, the Cherokee Nation Tribal Courts reinstated the Cherokee Freedmen as citizens while appeals were pending in the Cherokee Nation Courts and Federal Court. On May 22, 2007, the Cherokee Nation received notice from the United States Bureau of Indian Affairs that the BIA and Federal Government had denied the amendment to the 1975 Cherokee Nation Constitution because it required BIA approval, which had not been obtained. The BIA also noted that the Cherokee Nation had excluded the Cherokee Freedmen from voting on the amendment. On this issue, the Cherokee Nation Supreme Court ruled that the Cherokee Nation could take away the approval authority which it had previously granted the federal government.
=== Expansion === In 1994, Dane and Travis Boersma struck a deal with a customer, Marty McKenna, which allowed him to open his own Dutch Bros in Medford, about 30 miles away from Grants Pass. McKenna's first stand performed so well that he soon opened up a second one across town. In 1997, the Boersmas brought McKenna on as a partner, hoping he would continue to expand the Medford operations. Two years later, they bought out McKenna's stake in the company. In 1999, Dutch Bros started formally franchising. The company opened its 50th franchised drive-thru location in 2004. That same year, shortly after moving into a new headquarters in Grants Pass, a nearby dumpster fire spread to the building, destroying Dutch Bros roasting equipment, five vehicles, and thousands of pounds of coffee beans. Following this incident, the company continued to expand, and by the end of 2004, operated 61 coffee shops spanning from Northern California to Oregon's Willamette Valley. By 2009, Dutch Bros was running about 135 coffee stands in seven states and generating $50 million in gross annual revenue. Dane Boersma died in 2009 from amyotrophic lateral sclerosis. In 2013, Travis Boersma was featured on the American version of the television show Undercover Boss. Revenues continued to grow into the mid-2010s. The company earned $238 million in systemwide sales in 2015, $350 million in 2016, and $415.3 million in 2017, when over 283 Dutch Bros locations were operating.
High-strength alloy steel remains the primary material for submarines today, with 250–400-metre (820–1,310 ft) depths, which cannot be exceeded on a military submarine without design compromises. To exceed that limit, a few submarines were built with titanium hulls. Titanium alloys can be stronger than steel, lighter, and most importantly, have higher immersed specific strength and specific modulus. Titanium is also not ferromagnetic, important for stealth. Titanium submarines were built by the Soviet Union, which developed specialized high-strength alloys. It has produced several types of titanium submarines. Titanium alloys allow a major increase in depth, but other systems must be redesigned to cope, so test depth was limited to 1,000 metres (3,300 ft) for the Soviet submarine K-278 Komsomolets, the deepest-diving combat submarine, though continuous operation at such depths would produce excessive stress on many submarine systems. Titanium does not flex as readily as steel, and may become brittle after many dive cycles. Despite its benefits, the high cost of titanium construction led to the abandonment of titanium submarine construction as the Cold War ended. Deep-diving civilian submarines have used thick acrylic pressure hulls. Although the specific strength and specific modulus of acrylic are not very high, the density is only 1.18g/cm3, so it is only very slightly denser than water, and the buoyancy penalty of increased thickness is correspondingly low. The deepest deep-submergence vehicle (DSV) to date is Trieste.
Klibanski became chief of the Neuroendocrine Unit at Massachusetts General Hospital, studying hormones and neuroendocrinology with a focus on hypopituitarism and pituitary tumors. Her clinical research has also examined the effects of hypothalamic and pituitary disorders on body composition and bone density, including bone loss associated with anorexia nervosa and growth hormone deficiency. In 1997, Klibanski became the first woman from Mass General's Department of Medicine to become a professor of medicine at Harvard. She has authored more than 350 peer-reviewed papers and book chapters and has received the Endocrine Society Clinical Investigator Award and the Clinical Endocrinology Trust Medal from the Society for Endocrinology. Klibanski has served on the National Institute of Diabetes and Digestive and Kidney Diseases Board of Counselors and the editorial board of the Journal of Clinical Endocrinology and Metabolism, and is a past president of the Pituitary Society. She established the Center for Faculty Development at Massachusetts General Hospital and mentored more than fifty women, for which she received the Endocrine Society's Outstanding Mentor Award.
Sources: en.wikipedia.org
Np(IV) or Np4+ is pale yellow-green in acidic solutions, where it exists as hydrated complexes (Np(H2O)4+n). It is quite unstable to hydrolysis in acidic aqueous solutions at pH 1 and above, forming NpOH3+. In basic solutions, Np4+ tends to hydrolyze to form the neutral neptunium(IV) hydroxide (Np(OH)4) and neptunium(IV) oxide (NpO2). Neptunium(V)
Pioglitazone (Actos), France and Germany have suspended its sale after a study suggested the drug could raise the risk of bladder cancer. Rosiglitazone (Avandia), which was put under selling restrictions in the US and withdrawn from the market in Europe due to some studies suggesting an increased risk of cardiovascular events. Upon re-evaluation of new data in 2013, the FDA lifted the restrictions. Lobeglitazone (Duvie), approved for use in South Korea Experimental, failed and non-marketed agents include:
The commission noted "numerous cases of illegal detention of civilians, arbitrary arrests, abduction and taking of hostages, mostly committed by South Ossetian forces and other South Ossetian armed groups." The commission concluded: "The Russian authorities and the South Ossetian authorities failed overwhelmingly to take measures to maintain law and order and ensure the protection of the civilian population as required under IHL and HRL." The commission noted that "some violations of IHL and HRL during the conflict and its aftermath were motivated by referring to “thousands of civilian casualties in South Ossetia,” as reported by Russian federal TV channels."
== External links == Pharmaceutical Inspection Cooperation Scheme: GMP Guides World Health Organization GMP Guidelines European Union GMP Guidelines US CFR Title 21 parts 210 (GMP, general), 211 (GMP, finished pharmaceuticals), 212 (GMP, positron emission tomography drugs), 225 (GMP, medicated feeds), 226 (GMP, type A medicated articles). Report on Optimizing and Leaning GMP Batch Record Design
Sources: en.wikipedia.org
Due to increased sensitivity and potentially dangerous adverse events among elderly patients, it is recommended to avoid prescribing them as specified by the 2015 American Geriatrics Society Beers Criteria. Individuals with an impaired liver also metabolize benzodiazepines more slowly. Thus, the approximate equivalent of doses below may need to be adjusted accordingly in individuals on short acting benzodiazepines who metabolize long-acting benzodiazepines more slowly and vice versa. The changes are most notable with long acting benzodiazepines as these are prone to significant accumulation in such individuals and can lead to withdrawal symptoms. For example, the equivalent dose of diazepam in an elderly individual on lorazepam may be half of what would be expected in a younger individual. Equivalent doses of benzodiazepines differ as much as 20 fold.
=== May === May 1 – Lubbock, Texas votes to become the largest city in U.S. to ban abortion with the "sanctuary city for the unborn". May 4 – COVID-19 pandemic – Michigan relaxes several restrictions regarding face mask requirements and outdoor gatherings. May 5 – South Carolina House votes to add firing squad to execution methods; South Carolina would become the fourth state to use firing squad after Mississippi, Oklahoma and Utah. May 7 Colonial Pipeline cyberattack: An oil pipeline in Houston is hacked by DarkSide causing the pipeline operator to shut down its entire network, the source of nearly half of the U.S. East Coast's fuel supply. COVID-19 vaccines – Pfizer/BioNTech seek full approval from the FDA for the Pfizer–BioNTech COVID-19 vaccine. May 9 – 2021 Colorado Springs shooting: Seven people are shot dead at a birthday party in Colorado Springs, Colorado. May 10 – COVID-19 vaccination: The FDA authorizes the Pfizer–BioNTech COVID-19 vaccine for adolescents aged 12–15 years old. May 11 – The Colonial Pipeline shutdown enters its fifth day. Panic buying by motorists causes many eastern seaboard gas stations to begin running dry. U.S. Energy Secretary Jennifer Granholm urges calm and to not hoard. May 12 Colonial Pipeline begins restarting, but warns that it will take several days for things to return to normal operations. COVID-19 vaccination – The Centers for Disease Control and Prevention (CDC) adopts the FDA recommendation to provide the Pfizer–BioNTech vaccine to adolescents aged 12–15 years old.
In chemical analysis, chromatography is a laboratory technique for the separation of a mixture into its components. The mixture is dissolved in a fluid solvent (gas or liquid) called the mobile phase, which carries it through a system (a column, a capillary tube, a plate, or a sheet) on which a material called the stationary phase is fixed. As the different constituents of the mixture tend to have different affinities for the stationary phase and are retained for different lengths of time depending on their interactions with its surface sites, the constituents travel at different apparent velocities in the mobile fluid, causing them to separate. The separation is based on the differential partitioning between the mobile and the stationary phases. Subtle differences in a compound's partition coefficient result in differential retention on the stationary phase and thus affect the separation. Chromatography may be preparative or analytical. The purpose of preparative chromatography is to separate the components of a mixture for later use, and is thus a form of purification. This process is associated with higher costs due to its mode of production. Analytical chromatography is done normally with smaller amounts of material and is for establishing the presence or measuring the relative proportions of analytes in a mixture. The two types are not mutually exclusive.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.